| Angiomyolipoma |
| Classification and external resources |
Angiomyolipoma in both kidneys (arrows) in computer tomography. The tumours are hypodense (dark) due to fat content |
| ICD-10 |
D30.0 |
| ICD-9 |
223.0 |
| ICD-O: |
M8860/0 |
| DiseasesDB |
29496 |
| MeSH |
D018207 |
Angiomyolipomas are the most common benign tumour of the kidney and are composed of blood vessels, smooth muscle cells and fat cells. Angiomyolipomas are strongly associated with the genetic disease tuberous sclerosis, in which most individuals will have several angiomyolipomas affecting both kidneys. They are also commonly found in women with the rare lung disease lymphangioleiomyomatosis. Angiomyolipomas are less commonly found in the liver and rarely in other organs. Whether associated with these diseases or sporadic, angiomyolipomas are caused by mutations in either the TSC1 or TSC2 genes, which govern cell growth and proliferation.
Although regarded as benign, angiomyolipomas may grow such that kidney function is impaired or the blood vessels may dilate and burst leading to haemorrhage. Large angiomyolipoma can be treated with embolisation. Drug therapy for angiomyolipoma is at the research stage.
|
Contents
- 1 Classification
- 2 Symptoms
- 3 Pathophysiology
- 4 Diagnosis
- 5 Treatment
- 6 Prognosis
- 7 Epidemiology
- 8 References
|
Classification
Angiomyolipomas are tumours consisting of perivascular epithelioid cells (cells which are found surrounding blood vessels and which resemble epithelial cells). A tumour of this kind is known as a PEComa, from the initials of perivascular epithelioid cell. Older literature may classify them as hamartomas (benign tumours consisting of cells in their correct location but forming a disorganised mass) or choristoma (benign tumours consisting of normal cells in the wrong location). PEComas are themselves a kind of mesenchymal tumour which involves cells that form the connective tissue, cardiovascular and lymphatic systems.[1]
An angiomyolipoma is composed of varying proportions of vascular cells, immature smooth muscle cells and fat cells.[1] These three components respectively give rise to the components of the name: angio-, myo- and lip-. The -oma suffix is indicates a tumour.
Angiomyolipomas are typically found in the kidney but have also been commonly found in the liver and less commonly the ovary, fallopian tube, spermatic cord, palate and colon.[1]
Symptoms
If the dilated blood vessels in an angiomyolipoma rupture, the resulting retroperitoneal haemorrhage causes sudden pain, accompanied with nausea and vomiting. When the patient presents in the emergency department, up to 20% will be in shock.[1]
Pathophysiology
Myoid cells with clear cytoplasm spinning off of large vessels in a background of mature fat: the classic microscopic features of angiomyolipoma.
Since all three components of an angiomyolipoma (vascular cells, immature smooth muscle cells and fat cells) contain a "second hit" mutation, they are believed to have derived from a common progenitor cell that suffered the common second hit mutation.[1]
Diagnosis
There are three methods of scanning that detect angiomyolipoma: ultrasound, CT and MRI. Ultrasound is standard and is particularly sensitive to the fat in angiomyolipoma but less so to the solid components. However it is hard to make accurate measurements with ultrasound. Computed tomography (CT) is very detailed and fast and allows accurate measurement. However, it exposes the patient to radiation and the dangers that a contrast dye used to aid the scanning may itself harm the kidneys. Magnetic resonance imaging (MRI) is safer than CT but many patients (particularly those with the learning difficulties or behavioural problems found in tuberous sclerosis) require sedation or general anaesthesia and the scan cannot be performed quickly.[1] Some other kidney tumours contain fat, so the presence of fat isn't diagnostic. It can be difficult to distinguish a fat-poor angiomyolipoma from a renal cell carcinoma[2] and a lesion growing at greater than 5 mm per year may warrant a biopsy in order to distinguish it from a from this form of cancer.[1]
Treatment
Angiomyolipoma do not normally require surgery unless there is life threatening bleeding.[2] Some centres may perform preventative selective embolisation of the angiomyolipoma if it is more than 4 cm in diameter, due to the risk of haemorrhage.[3]
People with tuberous sclerosis are advised to have yearly renal scans, though it is possible that patients with very stable lesions could be monitored less frequently. The research in this area is lacking. Even if no angiomyolipoma is found, one can develop at any life stage. The angiomyolipoma can grow rapidly.[1]
In tuberous sclerosis, there are typically many angiomyolipomas affecting each kidney. It is not uncommon for more than one intervention to be required during lifetime. Since kidney function may already be impaired (up to half the kidney may be lost before function loss is detectable), it is vital to preserve as much kidney as possible when removing any lesion. Large angiomyolipomas are treated by embolisation which reduces the risk of haemorrhage and can also shrink the lesion. A side effect of this treatment is postembolisation syndrome: severe pain and fever however this is easily managed and lasts only a few days.[1]
A ruptured aneurysm in an angiomyolipoma leads to blood loss that must be stopped (though embolisation) and compensated for (through intravenous fluid replacement). Therefore, removal of the affected kidney (nephrectomy) is strongly discouraged though may occur if the emergency department is not knowledgeable about tuberous sclerosis.[1]
Embolisation involves inserting a catheter along the blood vessels to the tumour. The blood vessels are then blocked, typically by injecting ethanol or inert particles. The procedure can be very painful, so analgesics are used. The destroyed kidney tissue often causes post-embolisation syndrome, which manifests as nausea, vomiting, fever and abdominal pain, and lasts a few days. Embolisation (in general) has an 8% rate of morbidity and a 2.5% rate of mortality, so is not considered lightly.[3]
Patients with kidney loss should be monitored for hypertension (and treated for it if discovered) and avoid nephrotoxic drugs such as certain pain relievers and IV contrast agents. Such patients who are unable to communicate effectively (due to age or intellectual disability) are at risk of dehydration. Where multiple or large angiomyolipomas have caused chronic kidney disease, dialysis is required.[1]
Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken. Small studies showed the lesions shrank but that the drugs were often toxic. The use of these drugs remains at the research stage.[1]
Prognosis
Small angiomyolipomas and those without dilated blood vessels (aneurysms) cause few problems, but angiomyolipomas have been known to grow as rapidly as 4 cm in one year. An angiomyolipoma larger than 5 cm and those containing an aneurysm pose a significant risk of rupture, which is a medical emergency as it is potentially life threatening. One population study found the cumulative risk of haemorrhage to be 10% in males and 20% in females.[1]
A second problem occurs when the renal angiomyolipomas take over so much kidney that the function is impaired leading to chronic kidney disease. This may be severe enough to require dialysis. A population survey of patients with TSC and normal intelligence found 1% were on dialysis.[1]
Epidemiology
Angiomyolipomas are the most common benign tumour of the kidney and are found either in patients with tuberous sclerosis or sporadically. About 80–90% of cases are sporadic and these are most commonly found in middle-aged women.[2]
In patients with TSC, a longitudinal study found 80% will have some form of renal lesion by around 10 years of age. Of these, 75% are angiomyolipomas and 17% cysts. The angiomyolipomas increased in size in around 60% of these children. An autopsy study and TSC clinic survey found a prevalence of 67% and 85% respectively for patients with TSC. Both genders are affected equally.[1]
References
- ^ a b c d e f g h i j k l m n o Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.
- ^ a b c Shin NY, Kim MJ, Chung JJ, Chung YE, Choi JY, Park YN. The differential imaging features of fat-containing tumors in the peritoneal cavity and retroperitoneum: the radiologic-pathologic correlation. (PDF) Korean J Radiol. 2010 May–Jun;11(3):333–45. PMID 20461188.
- ^ a b Loffroy R, Rao P, Kwak BK, Ota S, De Lin M, Liapi E, Geschwind JF. Transcatheter arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications. Korean J Radiol. 2010 May–Jun;11(3):257–68. PMID 20461179.
|
Connective/soft tissue tumors and sarcomas (ICD-O 8800–9059) (C45–C49/D17–D21, 171/214–215)
|
|
| Not otherwise specified (8800–8809) |
Soft tissue sarcoma · Desmoplastic small round cell tumor
|
|
| Connective tissue neoplasm |
|
Fibromatous (8810–8839)
|
Fibroma/fibrosarcoma: Dermatofibrosarcoma · Dermatofibrosarcoma protuberans · Desmoplastic fibroma
Fibroma/fibromatosis: Aggressive infantile fibromatosis · Aponeurotic fibroma · Collagenous fibroma · Diffuse infantile fibromatosis · Familial myxovascular fibromas · Fibroma of tendon sheath · Fibromatosis colli · Infantile digital fibromatosis · Juvenile hyaline fibromatosis · Plantar fibromatosis · Pleomorphic fibroma · Oral submucous fibrosis
Histiocytoma/histiocytic sarcoma: Benign fibrous histiocytoma · Malignant fibrous histiocytoma · Atypical fibroxanthoma
Solitary fibrous tumor
|
|
|
Myxomatous (8840–8849)
|
Myxoma/myxosarcoma (Cutaneous myxoma, Superficial acral fibromyxoma) · Angiomyxoma · Ossifying fibromyxoid tumour
|
|
|
Fibroepithelial (9000–9039)
|
Brenner tumour · Fibroadenoma · Phyllodes tumor
|
|
|
Synovial-like (9040–9049)
|
Synovial sarcoma · Clear-cell sarcoma
|
|
|
| Lipomatous (8850–8889) |
Lipoma/liposarcoma (Myelolipoma, Myxoid liposarcoma) · PEComa (Angiomyolipoma)
Chondroid lipoma · Intradermal spindle cell lipoma · Pleomorphic lipoma · Benign lipoblastomatosis · Spindle cell lipoma · Hibernoma
|
|
| Myomatous (8890–8929) |
general: Myoma/myosarcoma
smooth muscle: Leiomyoma/leiomyosarcoma
skeletal muscle: Rhabdomyoma/rhabdomyosarcoma: Embryonal rhabdomyosarcoma (Sarcoma botryoides) · Alveolar rhabdomyosarcoma
Leiomyoma · Angioleiomyoma · Angiolipoleiomyoma · Genital leiomyoma · Leiomyosarcoma · Multiple cutaneous and uterine leiomyomatosis syndrome · Multiple cutaneous leiomyoma · Neural fibrolipoma · Solitary cutaneous leiomyoma · STUMP
|
|
| Complex mixed and stromal (8930–8999) |
Adenomyoma · Pleomorphic adenoma · Mixed Müllerian tumor · Mesoblastic nephroma · Wilms' tumor · Rhabdoid tumour · Clear-cell sarcoma of the kidney · Hepatoblastoma · Pancreatoblastoma · Carcinosarcoma
|
|
| Mesothelial (9050–9059) |
Mesothelioma · Adenomatoid tumor
|
|
|
see also Template:Connective tissue
|
|
anat (h/n, u, t/d, a/p, l)/phys/devp/hist
|
noco(m, s, c)/cong(d)/tumr, sysi/epon, injr
|
|
|
|
|
|
Tumors: urogenital neoplasia: urinary organs (C64–C68/D30, 188–189/223)
|
|
| Abdominal |
|
Kidney
|
Glandular and epithelial neoplasm: Renal cell carcinoma · Renal oncocytoma
Complex and mixed tumor: Wilms' tumor · Mesoblastic nephroma · Clear-cell sarcoma of the kidney · Angiomyolipoma · Cystic nephroma · Metanephric adenoma
by location: Renal medullary carcinoma · Juxtaglomerular cell tumor · Renal medullary fibroma
|
|
|
Ureter
|
Ureteral neoplasm
|
|
|
| Pelvic |
|
Bladder
|
Transitional cell carcinoma · Inverted papilloma · Squamous cell carcinoma
|
|
|
Urethra
|
Transitional cell carcinoma · Squamous cell carcinoma · Adenocarcinoma · Melanoma
|
|
|
| Retroperitoneum |
Malignant fibrous histiocytoma
|
|
|
|
|
noco/acba/cong/tumr, sysi/epon, urte
|
proc/itvp, drug (G4B), blte, urte
|
|
|
|
